Compare Hims and Hers Health Inc (HIMS) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Jabil Inc — how do they compare? Hims and Hers Health Inc trades at $29.33 (market cap $6.55B), while Jabil Inc trades at $302.22 (market cap $31.35B). The key difference: Jabil Inc is far larger — about 4.8× Hims and Hers Health Inc's market cap, and Jabil Inc pays a 0.11% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Jabil Inc for 23 Days on average.
| HIMS | JBL | |
|---|---|---|
Market Cap | $6.55B | $31.35B |
Volume | 14,842,814 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $62.76 | $385.50 |
52-Week Low | $14.52 | $192.49 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $7.25B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
JBL trades at $301.76, up 0.76% today, with a bearish technical signal despite strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $29.80B in 2025 and a high ROE of 74.11%, though net margins are thin at 2.9%. AI infrastructure demand is driving optimistic fiscal 2027 guidance, with a consensus analyst price target of $434.75 implying significant upside.
The outlook is positive due to accelerating AI-led growth and strong analyst support, but risks include market volatility post-earnings and high valuation multiples. Investment appeal hinges on execution of projected 24% revenue growth, while current technical weakness may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
